Skip to main content
Back
UTHR logo

United Therapeutics Corporation

Data quality: 100%
UTHR
NASDAQ Healthcare Biotechnology
$541.60
▲ $9.78 (1.84%)
Mkt Cap: 23.74B
Day Range
$536.92 $549.50
52-Week Range
$266.98 $549.50
Volume
528,650
50D / 200D Avg
$491.10 / $415.89
Prev Close
$531.82

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 17.8 0.3
P/B 3.4 3.0
ROE % 19.7 3.7
Net Margin % 41.9 3.8
Rev Growth 5Y % 17.2 10.0
D/E 0.0 0.2

Analyst Price Target

Hold
$579.83 +7.1%
Low: $447.00 High: $645.00
Forward P/E
18.41
Forward EPS
$29.41
EPS Growth (est.)
+0.0%
Est. Revenue
3.34B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $53.13
$46.51 – $59.63
 5.78B 4
FY2029 $46.47
$40.68 – $52.15
 5.06B 4
FY2028 $38.67
$27.43 – $51.06
 4.31B 10

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 $7.13 $7.70 +8.0%
2025-10-29 $6.89 $7.16 +3.9%
2025-07-30 $7.29 $6.41 -12.1%
2025-04-30 $6.29 $6.63 +5.4%
2025-02-26 $6.40 $6.19 -3.3%
2024-10-30 $6.43 $6.39 -0.6%
2024-07-31 $6.40 $5.85 -8.6%
2024-05-01 $5.65 $6.17 +9.2%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue grew 17.22% annually over 5 years — strong growth
ROE of 19.71% — decent returns on equity
Net margin of 41.94% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 1.04B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6.61%

Growth

Revenue Growth (5Y)
17.22%
Revenue (1Y)10.61%
Earnings (1Y)11.68%
FCF Growth (3Y)17.99%

Quality

Return on Equity
19.71%
ROIC15.77%
Net Margin41.94%
Op. Margin46.89%

Safety

Debt / Equity
0.00
Current Ratio6.60
Interest Coverage76.54

Valuation

P/E Ratio
17.78
Forward P/E17.72
P/B Ratio3.35
EV/EBITDA14.86
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.61% Revenue Growth (3Y) 16.94%
Earnings Growth (1Y) 11.68% Earnings Growth (3Y) 16.42%
Revenue Growth (5Y) 17.22% Earnings Growth (5Y) 29.42%
Profitability
Revenue (TTM) 3.18B Net Income (TTM) 1.33B
ROE 19.71% ROA 16.94%
Gross Margin 87.92% Operating Margin 46.89%
Net Margin 41.94% Free Cash Flow (TTM) 1.04B
ROIC 15.77% FCF Growth (3Y) 17.99%
Safety
Debt / Equity 0.00 Current Ratio 6.60
Interest Coverage 76.54
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 17.78 Forward P/E 17.72
P/B Ratio 3.35 P/S Ratio 7.46
PEG Ratio 1.16 Forward PEG N/A
EV/EBITDA 14.86 Fwd EV/EBITDA 9.66
Forward P/S 7.11 Fwd Earnings Yield 5.64%
FCF Yield 4.38%
Market Cap 23.74B Enterprise Value 22.18B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.18B 2.88B 2.33B 1.94B 1.69B
Net Income 1.33B 1.20B 984.80M 727.30M 475.80M
EPS (Diluted) 27.86 24.64 19.81 15.00 10.06
Gross Profit 2.80B 2.57B 2.07B 1.79B 1.56B
Operating Income 1.49B 1.38B 1.18B 979.70M 555.90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.88B 7.36B 7.17B 6.04B 5.17B
Total Liabilities 783.80M 920.00M 1.18B 1.25B 1.21B
Shareholders' Equity 7.10B 6.44B 5.98B 4.80B 3.96B
Total Debt 0.0 300.00M 700.00M 800.00M 800.00M
Cash & Equivalents 1.56B 1.70B 1.21B 961.20M 894.80M
Current Assets 3.70B 3.87B 3.55B 3.38B 2.32B
Current Liabilities 560.60M 738.10M 804.40M 343.20M 305.40M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Balanced Risk
#105 of 151
41

Recent Activity

Entered Balanced Risk
Mar 24, 2026